{
  "id": 1502295,
  "title": "Kelun-Biotech H1 2026 presentation: commercialization revenue surges 112%",
  "url": "https://urgent.news/2026/08/17/kelun-biotech-h1-2026-presentation-commercialization-revenue-surges",
  "topic": "finance",
  "section": "Finance & Markets",
  "published": "2026-08-17T15:12:49.000Z",
  "source": {
    "name": "Investing.com",
    "slug": "investing-com",
    "url": "https://www.investing.com/news/company-news/kelunbiotech-h1-2026-presentation-commercialization-revenue-surges-112-93CH-4863596"
  },
  "original_language": "en",
  "account": "On August 17, Kelun-Biotech (HKEX:6990) unveiled its H1 2026 financial results, highlighting a significant shift from a research-oriented approach to a commercial-focused business model. The company disclosed that commercialization revenue surged 112% year-over-year to RMB 657 million, accounting for 67% of total revenue. This transition to a commercial enterprise resulted in profitability, with an adjusted net profit of RMB 479 million, in contrast to a loss of RMB 145 million in the previous year. The company’s stock price rose to $522.5 following the announcement, marking a 33% increase year-to-date.\n\nThe H1 2026 financial overview revealed total revenue of RMB 978.3 million, a modest 2.9% increase from the prior year, but with a substantial transformation in revenue composition. Commercial sales of pharmaceutical products surged 112% year-over-year, reaching RMB 657 million, while revenue from licensing and collaboration agreements contributed RMB 309.8 million. Gross profit expanded by 11.7% to RMB 736.9 million, reflecting a gross margin of 75.36%, showcasing robust operational efficiency. However, the intensified commercial scale-up required significant investment, with research and development expenses increasing by 25.7% to RMB 768.4 million, and sales and distribution expenses more than doubling to RMB 390.6 million.\n\nKelun-Biotech positioned itself as an integrated biopharmaceutical company, boasting three proprietary technology platforms: biologics, antibody-drug conjugates (ADCs), and small molecules. The company proudly announced its status as one of the first ADC developers in China, with over a decade of experience. A notable achievement was the establishment of an ADC collaboration with the top global biopharmaceutical company, MSD (Merck Sharp & Dohme), which also holds a significant stake in Kelun-Biotech.\n\nAs of June 30, 2026, Kelun-Biotech employed approximately 2,300 individuals, with a notable increase in its commercialization team to nearly 800 professionals, nearly doubling year-over-year. The company’s pipeline comprised 30+ assets, including 10 in clinical trials, 4 products on the market for various indications, and 3 new drug applications submitted. Sac-TMT, their flagship ADC, has secured approval for four indications, including second-line or later triple-negative breast cancer, third-line EGFR-mutated non-small cell lung cancer, and others. The company's commercial reach expanded to 30 provinces, over 300 cities, and more than 2,000 hospitals across China, with significant market access milestones achieved in 2026.\n\nKey drivers behind Kelun-Biotech’s commercial momentum included expert recognition of its high-quality clinical data, leading to guideline recommendations, and comprehensive enhancements to drug accessibility through insurance coverage, hospital access channels, and expanded sales force. The company's clinical development strategy focused on oncology ADCs and novel drug conjugates, with Sac-TMT at the forefront of its global program, evolving from late-line monotherapy to first-line combination therapy across multiple tumor types.",
  "summary": null,
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}